Depomed Hits Endo With Patent Suit Over Opana ER

Law360, New York (April 18, 2013, 2:40 PM EDT) -- Depomed Inc. on Wednesday sued Endo Pharmaceuticals Inc. in New Jersey federal court, accusing Endo's painkiller Opana ER of infringing three patents for extended-release drug technology.

According to the complaint, Opana ER, the extended-release version of opioid painkiller oxymorphone, infringes on three Depomed patents — U.S. Patent Numbers 6,340,475 and 6,635,280, both titled, "Extending the duration of drug release within the stomach during the fed mode," and 6,723,340, titled, "Optimal polymer mixtures for gastric retentive tablets."

"Depomed has been injured by defendant's infringing activities, and is...
To view the full article, register now.